Pineo GF, Hull RD, Brant RF, Elliott CG, Raskob GE, Feldstein W; International Society of Technology Assessment in Health Care. Meeting.
Annu Meet Int Soc Technol Assess Health Care Int Soc Technol Assess Health Care Meet. 1995; 11: Abstract No. 210.
The Canadian-American Thrombosis Group, Calgary, Alberta, Canada.
Low-molecular-weight heparin (LMWH) has a high bioavailability and a prolonged half-life in comparison with conventional unfractionated heparin. Currently data are unavailable for LMWH as compared with unfractionated heparin for the treatment of PE. In a multicentre, double-blind clinical trial, we compared fixed-dose subcutaneous LMWH (logiparin) given once daily with adjusted-dose IVH given by continuous infusion for the initial treatment of patients with objectively documented PE. None of 51 patients who received LMWH and 1 or 46 patients who received IVH (2.2%) had new episodes of venous thromboembolism (p=0.47, 95% confidence interval (CI) for the difference, -2.0% to 6.4%). No patients in either group had major bleeding, (95% CI for the observed difference of 0, -3.7% to 4.1%). One patient (2.0%) receiving LMWH died, as compared with 4 patients receiving IVH (8.7%) (p=0.2), 95% CI for the difference, -2.2% to 15.7%. LMWH is at least as effective as classic IVH therapy under the conditions of this study and more convenient to administer. Our findings support the effectiveness of LMWH in the treatment of patients with venous thromboembolism and extend the findings to patients with PE. Simplified therapy provided by LMWH may allow patients with uncomplicated PE to be cared for in an outpatient setting.
Publication Types:
Keywords:
- Double-Blind Method
- Hemorrhage
- Heparin
- Heparin, Low-Molecular-Weight
- Humans
- Logiparin
- Pulmonary Embolism
- Thromboembolism
- therapy
- hsrmtgs
Other ID:
UI: 102215956
From Meeting Abstracts